AppBlogHilfeonvista bank
Werbung ausblenden

News zu Gensight Biologics

GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting · Uhr · Business Wire
GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe · Uhr · Business Wire
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy · Uhr · Business Wire
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update · Uhr · Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial · Uhr · Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection · Uhr · Business Wire
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US · Uhr · Business Wire
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US · Uhr · Business Wire
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment · Uhr · Business Wire
GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022 · Uhr · Business Wire
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting · Uhr · Business Wire
GenSight Biologics Reports Cash Position as of September 30, 2021 and Provides Operational Update · Uhr · Business Wire
GenSight Biologics Provides Update on Manufacturing Timeline Needed for LUMEVOQ® Regulatory Filing · Uhr · Business Wire
Werbung ausblenden